

ASX:NRT
NASDAQ:NVGN

Novogen Ltd
(Company)

ABN 37 063 259 754

Capital Structure

Ordinary Shares on
issue:

483 M

Board of Directors

Mr John O'Connor
Chairman
Non-Executive Director

Mr Bryce Carmine
Deputy Chairman
Non-Executive Director

Dr James Garner
Chief Executive Officer
Managing Director

Mr Ian Phillips MNZM
Non-Executive Director

Mr Iain Ross
Non-Executive Director

Mr Steven Coffey
Non-Executive Director

MARKET RELEASE

15th March 2017

NOVOGEN SHAREHOLDER INFORMATION BRIEFING SESSIONS

Sydney, 15th March, 2017, Novogen Ltd (ASX: NRT; NASDAQ: NVGN), an Australian oncology-focused biotechnology company, is pleased to invite shareholders to attend information briefing sessions to discuss its clinical trials for GDC-0084 and Cantrixil, and recent updates in other areas.

Shareholder briefing sessions:

Shareholders wishing to register interest in attending one of the events outlined below, should RSVP by COB Monday, 3rd April 2017 by phoning Donna Cross on +61 2 9472 4101 or via the Novogen website, using this link: <http://www.novogen.com/common/contactus>. At the time of RSVP, please note your: name, email, contact number and which briefing session is of interest (Sydney or Melbourne.)

Melbourne:	Monday, 10 th April, 5:30-7:30pm Grant Thornton, The Rialto, Level 30, 525 Collins Street, Melbourne
Sydney:	Wednesday, 12 th April, 5:30-7:30pm Australian Institute of Company Directors, NSW Business Centre and Member Lounge, Level 1, 20 Bond Street, Sydney

Briefing webcast and Q+A session:

For those shareholders unable to attend the briefing sessions in person, Novogen will hold a question and answer session via webcast with CEO, Dr James Garner during the Sydney shareholder briefing session on Wednesday, 12th April at approximately at 5:30pm Australian Eastern Standard Time (AEST).


Shareholders are invited to submit questions ahead of the event for discussion during the session. To submit a question, please visit <http://www.novogen.com/common/contactus> and enter your question by close of business on Friday, 7th April.

To participate in the webcast, please visit:

<http://webcasting.boardroom.media/broadcast/58c79565596409733ddb670d>

to access the webcasting platform in time for a 5:30pm AEST start on Wednesday, 12th April, 2017.

[ENDS]



Media and investor relations

Glen Zurcher

E: glen.zurcher@irdepartment.com.au

T: +61 420 249 299

Investor relations (US)

Robert Kennedy

E: robert.kennedy@novogen.com

T: +1 212 519 9832 / +1 646 662 3574

About Novogen Limited

Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an emerging oncology-focused biotechnology company, based in Sydney, Australia. Novogen has a portfolio of four development candidates, diversified across three distinct technologies, with the potential to yield first-in-class and best-in-class agents across a range of oncology indications.

The lead program is GDC-0084, a small molecule inhibitor of the PI3K / AKT / mTOR pathway, which is being developed to treat glioblastoma multiforme. Licensed from Genentech in late 2016, GDC-0084 is anticipated to enter phase II clinical trials in 2017. Three further molecules have been developed in-house from two proprietary drug discovery platforms (superbenzopyrans and anti-tropomyosins) to treat ovarian cancer and a range of solid tumours. Cantrixil, the most advanced of these, commenced a first-in-human clinical study in patients with ovarian cancer in late 2016, while Anisina and Trilexium are in preclinical development. For more information, please visit: www.novogen.com

